# Effects of Dapagliflozin, Semaglutide, and Their Combination in Heart Failure Patients With Prosthetic Heart Valves

Study · id `cardio:ct-nct07610174` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07610174](<https://clinicaltrials.gov/study/NCT07610174>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07610174

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 160 participants.

## Technical summary

Registry record NCT07610174. Randomized; single masking; primary purpose treatment. Start 2025-06-02 (actual); primary completion 2026-04-29 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 160 participants (enrolled count; ClinicalTrials.gov record NCT07610174, source copy `cardio:ctgov-nct07610174-2026-05-29`, retrieved 2026-10-26)
- Started: 2025-06-02 (actual) (ClinicalTrials.gov record NCT07610174, source copy `cardio:ctgov-nct07610174-2026-05-29`, retrieved 2026-10-26)
- Primary completion: 2026-04-29 (actual) (ClinicalTrials.gov record NCT07610174, source copy `cardio:ctgov-nct07610174-2026-05-29`, retrieved 2026-10-26)
- Completion: 2026-04-29 (actual) (ClinicalTrials.gov record NCT07610174, source copy `cardio:ctgov-nct07610174-2026-05-29`, retrieved 2026-10-26)
- Countries: Egypt (ClinicalTrials.gov record NCT07610174, source copy `cardio:ctgov-nct07610174-2026-05-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07610174-2026-05-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effects of Dapagliflozin, Semaglutide, and Their Combination in Heart Failure Patients With Prosthetic Heart Valves
- Acronym: SYNCARDIA-HF
- Condition: Heart Failure
- Condition: Heart Valve Prosthesis
- Intervention (Drug): semaglutide
- Intervention (Drug): Dapagliflozin (10mg Tab)
- Lead sponsor: Kafrelsheikh University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry lists this organization as the lead sponsor: Kafrelsheikh University (`cardio:org-kafrelsheikh-university`)

## Provenance

Content hash: 0f3a45b011de7de48ec332f827e1d71dfc814a0b2a916072b54cab65907ec207
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
